Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.
Date: Wednesday 27th October
Time: 14:00 CEST
Dear ESID Member,
We and ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with GATA2 deficiency.
We consider this an important and timely survey. If your center has such patients, please consider, whether your center could participate in it.
Date: Tuesday 18th May
Time: 17:30-18:30 CET
With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals.